ARTICLE | Management Tracks
Brainard to succeed Hallal as AlloVir CEO; plus Illumina, NeoGenomics, Nordic Nanovector, Abeona, Delix and more
March 23, 2021 1:44 AM UTC
Diana Brainard will become CEO of AlloVir Inc. (NASDAQ:ALVR), succeeding David Hallal who will become executive chairman. Brainard is SVP and head of the virology therapeutic area at Gilead Sciences Inc. (NASDAQ:GILD). Before Gilead, Brainard worked for Merck & Co. Inc. (NYSE:MRK) in early drug development in clinical pharmacology and as the infectious diseases lead in translational medicine. Her appointment at AlloVir, is developing cell therapies for viral diseases, is effective May 17.
Jay Flatley is stepping down as chairman of Illumina Inc. (NASDAQ:ILMN) on May 26. He will be succeeded by John Thompson, a director. Flatley served as CEO for 17 years before he became executive chair in 2016...